Overview

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.

Phase:

Phase 4

Details

Lead Sponsor:

Allergan

Treatments:

Benzalkonium Compounds
Fluoroquinolones
Gatifloxacin
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ophthalmic Solutions
Pharmaceutical Solutions